Turim 21 Investimentos’s Alnylam Pharmaceuticals ALNY Stock Holding History

Turim 21 Investimentos’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3	Closed	–	–	111
2021 Q1	$0	Buy	+3	New	+$451	﹤0.01%	98

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Turim 21 Investimentos's ALNY Position: Q2 2021 in Review

Turim 21 Investimentos sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2021, closing a stake of 3 shares.

Turim 21 Investimentos first reported a position in ALNY in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 400 funds tracked by Wall St. Rank hold ALNY as of Q2 2021.

Turim 21 Investimentos reported no remaining Alnylam Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Turim 21 Investimentos sold 3 Alnylam Pharmaceuticals shares in Q2 2021.
Turim 21 Investimentos first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Turim 21 Investimentos's Alnylam Pharmaceuticals position peaked at $0 in Q1 2021.
400 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2021.

Based on Turim 21 Investimentos's 13F filing for Q2 2021, filed 13 Aug 2021.